Dermatomyositis: Clinical features and pathogenesis - 09/01/20

Doi : 10.1016/j.jaad.2019.06.1309

Madeline E. DeWane, BA ^a, Reid Waldman, MD ^b, Jun Lu, MD ^b,^⁎
^a University of Connecticut School of Medicine, Farmington, Connecticut
^b University of Connecticut Department of Dermatology, Farmington, Connecticut

^∗Reprint requests: Jun Lu, MD, Department of Dermatology, University of Connecticut, 21 South Rd, Farmington, CT 06032.Department of DermatologyUniversity of Connecticut21 South RdFarmingtonCT06032

Abstract

Dermatomyositis (DM) is an idiopathic inflammatory myopathy that is clinically heterogeneous and that can be difficult to diagnose. Cutaneous manifestations sometimes vary and may or may not parallel myositis and systemic involvement in time course or severity. Recent developments in our understanding of myositis-specific antibodies have the potential to change the diagnostic landscape of DM for dermatologists. Although phenotypic overlap exists, anti-Mi2, -MDA5, -NXP2, -TIF1, and -SAE antibodies may be correlated with distinct DM subtypes in terms of cutaneous manifestations, systemic involvement, and malignancy risk. This review highlights new findings on the DM-specific myositis-specific antibodies and their clinical associations in both adults and children.

Le texte complet de cet article est disponible en PDF.

Key words : amyopathic dermatomyositis, dermatomyositis, juvenile dermatomyositis, idiopathic inflammatory myopathy, interstitial lung disease, malignancy-associated dermatomyositis, Mi2, MDA5, myositis-specific antibodies, NXP2, SAE, TIF1

Abbreviations used : CADM, CAJDM, DM, IFN, IIM, ILD, JDM, MDA5, MSA, NXP2, RP-ILD